Pharmafile Logo

Paul Turnbull

- PMLiVE

FDA clears Dova drug for liver-related low blood platelets

Drug is in the same class as Novartis’ Promacta/Revolade

- PMLiVE

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

A rapid round up from the frontline of pharma, biotech and healthcare

- PMLiVE

Porterhouse Medical promotes Amanda Lyons

She becomes the agency’s senior account director

Dr Martin Rothman joins Sofinnova Partners

He becomes the firm’s venture partner

The NHS and ABPI at 70: inching closer to the triple win

The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...

Health Unlimited welcomes Ann Bartling in significant new PR hire

Monday 21 May, London: Global health consultancy and communications agency Health Unlimited has added to its senior talent in London with the hire of Ann Bartling as PR Practice Lead....

Health Unlimited

- PMLiVE

Positive mid-stage trial gives Allergy’s investors some welcome relief

Its grass pollen vaccine showed a “highly significant” dose response

Getting the sizing right

Merger and Acquisition activity in our sector can learn from the natural world

- PMLiVE

Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

AstraZeneca AZ

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links